Compare FLYX & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLYX | CING |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.1M | 64.5M |
| IPO Year | 2021 | 2021 |
| Metric | FLYX | CING |
|---|---|---|
| Price | $1.37 | $5.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | ★ 410.4K | 132.2K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.61 | ★ 56.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $375,877,000.00 | N/A |
| Revenue This Year | $10.47 | N/A |
| Revenue Next Year | $15.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.85 | N/A |
| 52 Week Low | $1.05 | $3.16 |
| 52 Week High | $8.88 | $11.89 |
| Indicator | FLYX | CING |
|---|---|---|
| Relative Strength Index (RSI) | 51.94 | 58.37 |
| Support Level | $1.05 | $5.08 |
| Resistance Level | $2.73 | $5.54 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 88.46 | 82.22 |
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet, which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.